-
193
-
63
-
54
-
50
-
49
Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Articles
-
Myelodysplastic syndromes
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009208PDF: 110 -
Organ damage and iron overload
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009291PDF: 1406 -
Progress in the management of iron overload in erytrocyte disorders
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009232PDF: 1704 -
Ph positive-leukemias
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009174PDF: 166 -
Thyrosin kinase inhibitors: nilotinib
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009370PDF: 439 -
New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009222PDF: 214 -
Peripheral T-cell lymphomas
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009265PDF: 587 -
Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009244PDF: 2273 -
A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009193PDF: 194 -
Chronic lymphocytic leukemia
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009201PDF: 2507 -
Monoclonal antibodies (update): CD20, rituximab
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009202PDF: 127 -
90Y-ibritumumab tiuxetan (Zevalin)
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009230PDF: 359 -
Update of alemtuzumab in the treatment of chronic lymphocytic leukaemia
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009191PDF: 220 -
Immunotherapy with epratuzumab in B-cell non-Hodgkin’s lymphoma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009157PDF: 363 -
New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009171PDF: 555 -
Update on galiximab: anti-CD80 monoclonal antibody
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009225PDF: 249 -
CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009655PDF: 2432 -
Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009275PDF: 338 -
Monoclonal antibodies (novel): humax-CD20, ofatumumab
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009197PDF: 208 -
Lumiliximab in chronic lymphocytic leukemia
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009183PDF: 443 -
Bevacizumab as an anti-VEGF strategy in lymphoma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009285PDF: 184 -
Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009197PDF: 275 -
Aurora kinase inhibitor: AS703569
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009218PDF: 285 -
From cell biology to therapy: lenalidomide in untreated multiple myeloma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009190PDF: 223 -
HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009470PDF: 601 -
Pha-739358: a pan-aurora kinase inhibitor
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009241Untitled (): 0PDF: 429 -
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009181PDF: 279 -
Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009357PDF: 419 -
From cell biology to therapy: forodesine
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009400PDF: 748 -
Flavopiridol (alvocidib) in chronic lymphocytic leukemia
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009322PDF: 796 -
mTOR inhibitors for the treatment of lymphoma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009201PDF: 328 -
Multiple myeloma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009151PDF: 98 -
Proteasome inhibitors: bortezomib in multiple myeloma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009182PDF: 211 -
Bortezomib in lymphomas
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009184PDF: 156 -
Proteasome inhibitors: beyond NFKB inhibition alone and the emerging role of combination therapy in the treatment of multiple myeloma
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009406PDF: 226 -
Novel proteasome inhibitors
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009208PDF: 328 -
Decitabine in myeloid malignancies
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009178PDF: 819 -
J-L. Harousseau Tipifarnib in hematologic malignancies
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009172PDF: 238 -
Is there a role for immunotherapy in Hodgkin’s disease?
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009158PDF: 559 -
New agents for the treatment of acute myeloid leukemia: midostaurin
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009225PDF: 882 -
Lestaurtinib as a FLT3 inhibitor
0000Smart Citations
View Citations0000Citing PublicationsSupportingMentioningContrastingSee how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Published: June 23, 2009157PDF: 170Untitled (): 0